United Kingdom

NantKwest Inc (NK.OQ)

NK.OQ on NASDAQ Stock Exchange Global Select Market

19 Apr 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Altor Bioscience and NantKwest announces co-development agreement
Tuesday, 4 Oct 2016 

NantKwest Inc: Financial terms of this co-development are not disclosed . Development agreement to advance innovative natural killer cell combination immunotherapies for the treatment of cancer . Altor and Co will exclusively collaborate on development of therapeutic applications combining altor's proprietary IL-15 superagonist .Altor, Co to also exclusively collaborate single-chain t cell receptor/IL-2 fusion protein products with Co's proprietary NK cell therapy platforms.  Full Article